Journal
EBIOMEDICINE
Volume 79, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ebiom.2022.104001
Keywords
Ovarian cancer; Biomarker; Multi-omics; Translational medicine
Funding
- National Natural Science Foundation of China (NSFC) [81672610, 81521002]
- Clinic + X program of Peking University
- China Postdoctoral Science Foundation [2021M700289]
- Boya postdoctoral program of Peking University
Ask authors/readers for more resources
This review summarizes the recent advances and perspectives in the use of multi-omics technologies in ovarian cancer research, highlighting their potential applications in identifying novel biomarkers and improving clinical assessments.
Ovarian cancer (OC) is a heterogeneous disease with the highest mortality rate and the poorest prognosis among gynecological malignancies. Because of the absence of specific early symptoms, most OC patients are often diagnosed at late stages. Thus, improved biomarkers of OC for use in research and clinical practice are urgently needed. The last decade has seen increasingly rapid advances in sequencing and biotechnological methodologies. Consequently, multiple omics technologies, including genomic/transcriptomic sequencings and proteomic/metabolomic mass spectra, have been widely applied to analyze tissue-and liquid-derived samples from OC patients. The integration of multi-omics data has increased our knowledge of the disease and identified valuable OC biomarkers. In this review, we summarize the recent advances and perspectives in the use of multi-omics technologies in OC research and highlight potential applications of multi-omics for identifying novel biomarkers and improving clinical assessments. Copyright (C) 2022 The Author(s). Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available